Comparison of remimazolam and midazolam administration in ketamin infusion therapy for chronic pain patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008955

Enrollment

Registered

2023-11-15

Start date

2022-08-19

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1) Research Method Overview To perform sedative treatment with ketamine and remimazolam or midazolam, the patient visits the hospital after fasting for more than 8 hours. Before sedation treatm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a target disease Chronic pain diseases subject to sedative treatment using ketamine, such as "complex regional pain syndrome," "fiber muscle pain," and "neuropathic pain." 2) Selection criteria and exclusion criteria of study subjects - Patients who are being treated for chronic pain for more than 6 months - Patients with neuropathic pain or fibromyalgia - Patients who agree with the study process

Exclusion criteria

Exclusion criteria: - Patients who are hypersensitive or allergic to ketamine, remimazolam, and midazolam - Drugs or alcoholics - Patients with heart disease such as angina, arrhythmia, and heart failure - Pregnant or potentially pregnant patients - Patients who disagree with the study

Design outcomes

Primary

Measure	Time frame
pain severity	—

Secondary

Measure	Time frame
side effects	—

Countries

Korea, Republic of

Contacts

Public ContactJae Hun Kim

Konkuk University Medical Center

painfree@kuh.ac.kr+82-2-2030-5749

Outcome results